Want to see MOVE full AI Analyst Report?
Corvex (MOVE) AI Stock Analysis
Corvex
(NASDAQ:MOVE)
MOVE scores low overall. The dominant factor is weak financial performance: the company remains unprofitable at every level, with a TTM net loss of $27.7M against just $4.4M of revenue, negative gross margin, and negative free cash flow of $19.9M. This is partly offset by a newly fortified balance sheet — roughly $573M of equity and minimal debt — which removes near-term solvency risk and funds the burn, though at the cost of likely significant shareholder dilution. Technicals compound the caution, with the price below all major moving averages, negative MACD, and depressed momentum readings amid high volatility (beta 1.87). Valuation provides no support given negative earnings and no dividend. The investment case rests entirely on management converting its large capital base into scaled, profitable revenue — an unproven outcome today.
Corvex (MOVE) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $210.77M
- Dividend Yield
- ―
- Average Volume (3M)
- 370.56K
- Price to Earnings (P/E)
- -0.5
- Beta (1Y)
- 1.94
- Revenue Growth
- 843.62%
- EPS Growth
- 21.98%
- Country
- US
- Employees
- 38
- Sector
- Technology
- Sector Strength
- 61
- Industry
- Software - Infrastructure
Corvex Business Overview & Revenue Model
Company Description
Corvex, Inc., an AI cloud computing company, provides GPU-accelerated infrastructure for AI workloads to customers worldwide. The company provides graphics processing unit accelerated compute, confidential computing, token factory, and inference serv...
How the Company Makes Money
Movano’s monetization is expected to come primarily from commercializing its device-and-software ecosystem. Potential revenue streams include: (1) sales of wearable hardware devices (one-time revenue per unit sold); (2) recurring software and service...
Corvex Earnings Call Summary
The earnings call highlighted several achievements, including successful sales of the Evie Rings, progress towards FDA clearance, and positive customer feedback. However, challenges such as stock price issues and financial concerns were also discussed. Overall, the sentiment leans slightly positive due to the company's forward momentum and strategic planning.
Q3-2024 Updates
Positive Updates
Negative Updates
Company Guidance
During the Movano Health Q3 2024 earnings call, the company provided guidance on several key metrics and strategic initiatives. Movano Health is optimistic about both its direct-to-consumer (D2C) and business-to-business (B2B) opportunities, emphasizing the EvieMed ring's anticipated FDA 510(k) clearance. The company has successfully shipped 339 Evie rings since resuming sales in September, achieving a 90%+ customer service approval score. It plans to capitalize on the upcoming Black Friday/Cyber Monday sales period with an entirely organic marketing strategy, resulting in efficient customer acquisition costs. Financially, Movano reported a Q3 operating loss of $7.4 million, down from $9.1 million in the previous year, with a cash position of $11.3 million as of September 30, 2024. The company continues to manage its cash burn carefully, which was approximately $5.6 million for the quarter. Additionally, Movano is exploring commercial opportunities with major pharmaceutical and healthcare partners, preparing for a pilot program in Q1 2025, and advancing its blood pressure and glucose monitoring technologies.
Corvex Financial Statement Overview
Summary
A sharply mixed picture. The balance sheet (score 71) is the clear strength following a major recapitalization: roughly $573M of equity, $599M of assets, and only $15M of debt (debt-to-equity of 0.03) remove near-term funding risk after equity was negative in fiscal 2025. However, the income statement (score 17) and cash flow (score 22) remain very weak. Revenue is inflecting from a tiny base (TTM $4.4M, up ~500%), but gross margin is still negative (about -6%), the TTM operating loss is $27.1M and net loss $27.7M — more than six times revenue — and the net loss widened versus 2025. Operations consumed $13.4M of cash with free cash flow of negative $19.9M, re-accelerating after an improved 2025. Ample capital capacity, but no demonstrated path to profitability yet, and the equity base implies substantial dilution.
Income Statement
17Very NegativeBalance Sheet
71PositiveCash Flow
22Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.43M | 433.00K | 1.01M | 0 | 0 | 0 |
| Gross Profit | -2.96M | -1.84M | -1.99M | -158.00K | -134.00K | 0 |
| EBITDA | -23.05M | -15.17M | -23.56M | -29.13M | -30.18M | -20.82M |
| Net Income | -27.65M | -18.29M | -23.73M | -29.28M | -30.20M | -22.58M |
Balance Sheet | ||||||
| Total Assets | 599.32M | 5.60M | 11.32M | 9.42M | 13.24M | 36.27M |
| Cash, Cash Equivalents and Short-Term Investments | 21.70M | 2.83M | 7.90M | 6.12M | 10.76M | 33.60M |
| Total Debt | 14.96M | 4.90M | 186.00K | 217.00K | 426.00K | 0 |
| Total Liabilities | 26.07M | 9.07M | 3.96M | 5.97M | 5.33M | 3.54M |
| Stockholders Equity | 573.25M | -3.47M | 7.36M | 3.45M | 7.92M | 32.73M |
Cash Flow | ||||||
| Free Cash Flow | -19.91M | -11.27M | -22.54M | -26.24M | -25.01M | -16.75M |
| Operating Cash Flow | -13.43M | -11.27M | -22.53M | -26.18M | -24.90M | -16.18M |
| Investing Cash Flow | 29.79M | 0 | -8,000 | -64.00K | 15.72M | -16.70M |
| Financing Cash Flow | 3.23M | 6.19M | 24.32M | 21.60M | 2.26M | 44.85M |
Corvex Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MOVE, the sentiment is Negative. The current price of 6.68 is below the 20-day moving average (MA) of 8.66, below the 50-day MA of 10.40, and below the 200-day MA of 13.01, indicating a bearish trend. The MACD of -1.04 indicates Positive momentum. The RSI at 28.21 is Positive, neither overbought nor oversold. The STOCH value of 11.27 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MOVE.
Corvex Risk Analysis
Corvex disclosed 89 risk factors in its most recent earnings report. Corvex reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksCorvex Peers Comparison
Overall Rating
BJDX44Neutral- MOVE40Underperform
AMIX40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 61Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% |
| BJDX | 44Neutral | $2.49M | -0.05 | -125.01% | ― | ― | 93.91% |
| MOVE | 40Underperform | $210.77M | -0.55 | -9.67% | ― | 843.62% | 21.98% |
| AMIX | 40Underperform | $3.55M | -0.04 | -267.73% | ― | ― | 64.78% |
* Technology Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| MOVE | Corvex, Inc. | 6.68 | 2.59 | 63.49% | |
| BBLG | Bone Biologics Corp | 0.38 | -1.66 | -81.37% | |
| BJDX | Bluejay Diagnostics, Inc. | 0.56 | -6.56 | -92.19% | |
| AMIX | Autonomix Medical, Inc. | 1.81 | -19.40 | -91.47% |
Corvex Corporate Events
Corvex Launches ATM Equity Program With Chardan Capital
PositiveOn October 14, 2026, Corvex, Inc. entered into an at-the-market sales agreement with Chardan Capital Markets LLC, appointing the firm as sales agent, and in certain periods as exclusive agent, to place shares of Corvex’s common stock under a sh...
Corvex finalizes Movano merger and equity restructuring
NeutralOn March 19, 2026, Corvex, Inc., formerly Movano Inc., completed its merger with Corvex Legacy Holdings, Inc., making Corvex OpCo a wholly owned subsidiary and later adopting the Corvex name on March 23, 2026. The consideration, structured through Se...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 15, 2026